Diabetes

Cambridge, MA, June 16,2016 - The Harvard Stem Cell Institute, three of Harvard’s clinical affiliates, and a biopharmaceutical company have formed a unique collaboration to establish the Boston Autologous Islet Replacement Program (BAIRT) to accelerate a...

Stem cell-derived, glucose-stimulated, insulin-producing cells (SC-β) are protected inside capsules engineered to be invisible to the host immune system. Photo courtesy of Omid Veiseh and Andrew Bader/Anderson/Langer Laboratory, Koch Institute at MIT...

Above, human brown fat progenitor cells express the calorie-burning, UCP1 proteins (green) as the cell differentiates. (Tseng Laboratory, Joslin Diabetes Center) Harvard Stem Cell Institute (HSCI) scientists at Harvard-affiliated Joslin Diabetes Center...

Mesenchymal stem cells (green) colonize a pancreatic islet in a preclinical model of diabetes. The blue dots represent the nuclei of cells within the islet. by Haley Bridger, Brigham and Women's Hospital Communications Researchers at Harvard-affiliated...

Harvard researchers have created a system using human stem cells to screen for compounds that have the potential to turn white, or “bad,” fat cells into brown, or “good,” fat cells. Pictured are human pluripotent stem cell-derived fat cells. (Photo Credit...

Joe Zhou, an associate professor in Harvard’s Department of Stem Cell and Regenerative Biology (Photo Credit: B. D. Colen) By B. D. Colen, Harvard Staff Writer Harvard Stem Cell Institute (HSCI) researchers at five different Harvard departments and...

Giant step toward new diabetes treatment Harvard stem cell researchers today announced that they have made a giant leap forward in the quest to find a truly effective treatment for type 1 diabetes, a condition that affects an estimated 3 million Americans...

Harvard Stem Cell Institute scientists at the Joslin Diabetes Center have created induced pluripotent stem cells (iPSCs) that offer a human model of insulin resistance—a key driver of type 2 diabetes. iPSCs are stem cells created by genetically modifying...

A portfolio of small molecules and biologics has been licensed by Harvard University and the Howard Hughes Medical Institute from the laboratory of Harvard Stem Cell Institute Co-Director Doug Melton, co-chair of Harvard’s Department of Stem Cell and...

Harvard Stem Cell Institute (HSCI) Co-director Douglas Melton, PhD, and Evotec AG have entered into their second research collaboration to find biological pathways and signals that could be therapeutically relevant to diabetic patients. The objective of...